Slovenya - Slovence - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ebewe pharma - metotreksat - raztopina za injiciranje v napolnjeni injekcijski brizgi - metotreksat 20 mg / 1 ml - metotreksat

Slovenya - Slovence - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ebewe pharma - metotreksat - raztopina za injiciranje v napolnjeni injekcijski brizgi - metotreksat 10 mg / 1 ml - metotreksat

Avrupa Birliği - Slovence - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cistična fibroza - drugi proizvodi dihal - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 in 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 in 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Slovenya - Slovence - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

egis pharmaceuticals plc - kvetiapin - filmsko obložena tableta - kvetiapin 100 mg / 1 tableta - kvetiapin

Slovenya - Slovence - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

egis pharmaceuticals plc - kvetiapin - filmsko obložena tableta - kvetiapin 150 mg / 1 tableta - kvetiapin

Slovenya - Slovence - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

egis pharmaceuticals plc - kvetiapin - filmsko obložena tableta - kvetiapin 150 mg / 1 tableta - kvetiapin

Slovenya - Slovence - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

egis pharmaceuticals plc - kvetiapin - filmsko obložena tableta - kvetiapin 100 mg / 1 tableta - kvetiapin

Slovenya - Slovence - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

egis pharmaceuticals plc - kvetiapin - filmsko obložena tableta - kvetiapin 200 mg / 1 tableta - kvetiapin

Slovenya - Slovence - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

egis pharmaceuticals plc - kvetiapin - filmsko obložena tableta - kvetiapin 300 mg / 1 tableta - kvetiapin

Slovenya - Slovence - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

egis pharmaceuticals plc - kvetiapin - filmsko obložena tableta - kvetiapin 300 mg / 1 tableta - kvetiapin